DIFFUSE LARGE B-CELL LYMPHOMA STAGE IV

This adverse event was reported 328 times

DIFFUSE LARGE B-CELL LYMPHOMA STAGE IV is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 SILTUXIMAB 2 0.0031
1 BARICITINIB 8 0.0026
2 POLATUZUMAB VEDOTIN 26 0.0025
3 TREOSULFAN 7 0.0025
4 MEGNESIUM OXIDE 1 0.0024
5 TAFASITAMAB-CXIX 2 0.0022
6 GLOFITAMAB 5 0.0018
7 RASBURICASE 4 0.0016
8 CARMUSTINE 6 0.0013
9 SODIUM HYALURONATE 1 0.0012
See all drugs enriched for association with DIFFUSE LARGE B-CELL LYMPHOMA STAGE IV